Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant in Asian Women with Menopausal Hot Flashes (Moonlight 1)
NCT04234204Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant group with Placebo group (2 arms). Primary endpoints: Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS) at 4 weeks and Mean change from baseline in the severity of moderate to severe vasomotor symptoms (VMS) at 4 weeks. Started Mar 2020; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04234204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234204.